In Tuesday’s Wall Street session, Viking Therapeutics Inc (NASDAQ:VKTX) shares traded at $23.91, down -0.99% from the previous session.
VKTX stock price is now -20.26% away from the 50-day moving average and -51.63% away from the 200-day moving average. The market capitalization of the company currently stands at $2.68B.
With the price target of $102, Scotiabank recently initiated with Sector Outperform rating for Viking Therapeutics Inc (NASDAQ: VKTX). On February 07, 2025, Citigroup recently initiated its ‘Neutral’ rating on the stock quoting a target price of $38, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, Lian Brian, President & CEO sold 194,490 shares of the company’s stock on Jan 06 ’25. The stock was sold for $8,313,601 at an average price of $42.75. Upon completion of the transaction, the President & CEO now directly owns 2,366,570 shares in the company, valued at $56.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 06 ’25, Chief Operating Officer Mancini Marianna sold 54,215 shares of the business’s stock. A total of $2,317,599 was realized by selling the stock at an average price of $42.75. This leaves the insider owning 374,134 shares of the company worth $8.95 million. A total of 2.94% of the company’s stock is owned by insiders.
During the past 12 months, Viking Therapeutics Inc has had a low of $23.27 and a high of $82.00. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 33.09, and a quick ratio of 33.09. The fifty day moving average price for VKTX is $29.9848 and a two-hundred day moving average price translates $49.427074 for the stock.
The latest earnings results from Viking Therapeutics Inc (NASDAQ: VKTX) was released for 2024-12-31.
